↓ Skip to main content

Cochrane Database of Systematic Reviews

Thrombolytic therapy for pulmonary embolism

Overview of attention for article published in Cochrane database of systematic reviews, July 2009
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (59th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
4 tweeters

Citations

dimensions_citation
59 Dimensions

Readers on

mendeley
77 Mendeley
Title
Thrombolytic therapy for pulmonary embolism
Published in
Cochrane database of systematic reviews, July 2009
DOI 10.1002/14651858.cd004437.pub3
Pubmed ID
Authors

Dong BR, Hao Q, Yue J, Wu T, Liu GJ

Abstract

Thrombolytic therapy is usually reserved for patients with clinically serious or massive pulmonary embolism (PE). Evidence suggests that thrombolytic agents may dissolve blood clots more rapidly than heparin and might reduce the death rate associated with PE. However, there are still concerns about the possible risk of adverse effects of thrombolytic therapy, such as major or minor haemorrhages. This is an update of a Cochrane review first published in 2006.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 77 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 3 4%
United States 1 1%
Singapore 1 1%
Brazil 1 1%
Unknown 71 92%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 17 22%
Other 14 18%
Researcher 10 13%
Professor > Associate Professor 7 9%
Student > Bachelor 5 6%
Other 15 19%
Unknown 9 12%
Readers by discipline Count As %
Medicine and Dentistry 57 74%
Agricultural and Biological Sciences 3 4%
Nursing and Health Professions 1 1%
Biochemistry, Genetics and Molecular Biology 1 1%
Pharmacology, Toxicology and Pharmaceutical Science 1 1%
Other 2 3%
Unknown 12 16%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 August 2013.
All research outputs
#6,486,603
of 12,101,174 outputs
Outputs from Cochrane database of systematic reviews
#5,867
of 7,978 outputs
Outputs of similar age
#58,965
of 148,636 outputs
Outputs of similar age from Cochrane database of systematic reviews
#73
of 107 outputs
Altmetric has tracked 12,101,174 research outputs across all sources so far. This one is in the 46th percentile – i.e., 46% of other outputs scored the same or lower than it.
So far Altmetric has tracked 7,978 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.6. This one is in the 26th percentile – i.e., 26% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 148,636 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.
We're also able to compare this research output to 107 others from the same source and published within six weeks on either side of this one. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.